180 related articles for article (PubMed ID: 3297068)
21. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
[TBL] [Abstract][Full Text] [Related]
22. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
[TBL] [Abstract][Full Text] [Related]
23. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
24. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding.
Elferink F; van der Vijgh WJ; Klein I; Pinedo HM
Clin Chem; 1986 Apr; 32(4):641-5. PubMed ID: 3513991
[TBL] [Abstract][Full Text] [Related]
25. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
26. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
Calvert AH; Harland SJ; Newell DR; Siddik ZH; Jones AC; McElwain TJ; Raju S; Wiltshaw E; Smith IE; Baker JM; Peckham MJ; Harrap KR
Cancer Chemother Pharmacol; 1982; 9(3):140-7. PubMed ID: 6761010
[TBL] [Abstract][Full Text] [Related]
27. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin.
Nonclercq D; Toubeau G; Laurent G; Tulkens PM; Heuson-Stiennon JA
Exp Mol Pathol; 1989 Oct; 51(2):123-40. PubMed ID: 2680578
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma.
Reece PA; Bishop JF; Olver IN; Stafford I; Hillcoat BL; Morstyn G
Cancer Chemother Pharmacol; 1987; 19(4):326-30. PubMed ID: 3036389
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of cis-dichlorodiammineplatinum.
Gormley PE; Bull JM; LeRoy AF; Cysyk R
Clin Pharmacol Ther; 1979 Mar; 25(3):351-7. PubMed ID: 761445
[TBL] [Abstract][Full Text] [Related]
31. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
Lelieveld P; Van der Vijgh WJ; Veldhuizen RW; Van Velzen D; Van Putten LM; Atassi G; Danguy A
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1087-104. PubMed ID: 6381064
[TBL] [Abstract][Full Text] [Related]
32. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.
Hannemann J; Baumann K
Arch Toxicol; 1990; 64(5):393-400. PubMed ID: 2169720
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
34. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.
Farris FF; King FG; Dedrick RL; Litterst CL
J Pharmacokinet Biopharm; 1985 Feb; 13(1):13-39. PubMed ID: 4040567
[TBL] [Abstract][Full Text] [Related]
35. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
36. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
Owens SE; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer JC; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1985; 14(3):253-7. PubMed ID: 3888431
[TBL] [Abstract][Full Text] [Related]
37. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
Jones AC; Wilson PA; Steel GG
Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
[TBL] [Abstract][Full Text] [Related]
38. Preclinical studies identifying carboplatin as a viable cisplatin alternative.
Harrap KR
Cancer Treat Rev; 1985 Sep; 12 Suppl A():21-33. PubMed ID: 3910219
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
40. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.
Gaver RC; George AM; Deeb G
Cancer Chemother Pharmacol; 1987; 20(4):271-6. PubMed ID: 3319277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
